Stabilized Coronavirus Spike (s) Protein Immunogens And Related Vaccines
The present invention provides redesigned soluble coronavirus S protein derived immunogens that are stabilized via specific modifications in the wildtype soluble S sequences. Also provided in the invention are nanoparticle vaccines that contain the redesigned soluble S immunogens displayed on self-assembling nanoparticles. Polynucleotide sequences encoding the redesigned immunogens and the nanoparticle vaccines are also provided in the invention. The invention further provides methods of using the vaccine compositions in various therapeutic applications, e.g., for preventing or treating coronaviral infections.
Claim CLM-00001. 1. An engineered immunogen polypeptide derived from the spike (S) protein of SARS-CoV-2, comprising the sequence shown in SEQ ID NO:33 or a conservatively modified variant thereof.
Claim CLM-03-17. 3-17. (canceled)
Claim CLM-00018. 18. A SARS-CoV-2 vaccine composition, comprising (1) a polypeptide sequence containing from N terminus to C terminus the engineered SARS-CoV-2 spike polypeptide shown in SEQ ID NO:33, linker sequence (G4S)2 (SEQ ID NO:22), nanoparticle sequence shown in SEQ ID NO:23, locking domain shown in SEQ ID NO:29, and T cell epitope shown in SEQ ID NO:30; or (2) a conservatively modified variant of the polypeptide sequence.
Claim CLM-00019. 19. The vaccine composition of claim Error! Reference source not found., comprising the sequence shown in SEQ ID NO:38.
Claim CLM-00020. 20. (canceled)
Claim CLM-00021. 21. A SARS-CoV-2 vaccine composition, comprising (1) a polypeptide sequence containing from N terminus to C terminus the engineered SARS-CoV-2 spike polypeptide shown in SEQ ID NO:33, linker sequence G4S (SEQ ID NO:21), nanoparticle subunit sequence shown in SEQ ID NO:24, locking domain shown in SEQ ID NO:28, and T cell epitope shown in SEQ ID NO:30; or (2) a conservatively modified variant of the polypeptide sequence.
